Mark has held a number of senior leadership roles throughout his 20 years’ experience in public and private healthcare. His appointment is announced as PBD Biotech declares its first multi-million pound funding round to support the test’s regulatory validation and ongoing commercialisation.

Commenting on his new role, Mark said, “I am excited about what the future holds for PBD Biotech, and keen to build on our fast-growing reputation as a leader in mycobacterial diagnostics.

Mark succeeds Dr Berwyn Clarke, who co-founded the company and, following his retirement as CEO, is to become a non-executive director on PBD Biotech’s Board.